About: Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys
Creator	Wang, Wei Zhou, Jun Hou, Wei Tang, Hongbing Tang, Zhijiao Wang, Yong Wen, Li Xian, Qiaoyang Xiao, Shu-Yuan Yang, Zhanqiu Zhong, Qiong Zhu, Runqing
Source	Elsevier; Medline; PMC
abstract	Abstract An inactivated vaccine for severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) was evaluated in rhesus monkeys. The monkeys were inoculated intramuscularly (i.m.) with 0.5, 5, 50, or 5000μg of vaccine, or PBS as control, and boosted on day 7. After 3 weeks, they were challenged with the NS-1 strain of SARS-CoV. The humoral and mucosal immune responses, clinical signs, chemical indices and viremia were monitored following the immunization and challenge. The control animals who received PBS developed atypical SAR-CoV infection after viral challenge, according to clinical, virological and pathological findings. No systematic side effects were observed in vaccinated animals post-immunization, even in at the high dose of 5000μg. The 50μg dosage of vaccine elicited SARS-CoV specific immune responses against viral infection as compared to the partial immunity elicited by 0.5 and 5μg doses. The results show that this inactivated vaccine can induce effective concomitant humoral and mucosal immunity against SARS-CoV infection, is safe in monkeys, and the vaccine maybe a good candidate for clinical trials.
has issue date	2005-05-02(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2004.11.075
bibo:pmid	15837221
has license	els-covid
sha1sum (hex)	57a851ef4ef9c13bc326a9c0e57bd24690694e06
schema:url	https://doi.org/10.1016/j.vaccine.2004.11.075
resource representing a document's title	Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys
has PubMed Central identifier	PMC7115379
has PubMed identifier	15837221
schema:publication	Vaccine
resource representing a document's body	covid:57a851ef4ef9c13bc326a9c0e57bd24690694e06#body_text
is schema:about of	named entity 'PATHOLOGICAL FINDINGS' named entity 'SARS-COV' named entity '3 WEEKS' named entity 'OBSERVED' named entity 'ACCORDING' named entity 'EFFECTIVE' named entity 'RECEIVED' named entity 'CONCOMITANT' named entity 'POST' named entity 'CLINICAL SIGNS' named entity '28I' named entity 'ANIMALS' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'GOOD' named entity 'HIGH DOSE' named entity 'DOSES' named entity 'ASSOCIATED' named entity 'IMMUNOGENICITY' covid:arg/57a851ef4ef9c13bc326a9c0e57bd24690694e06 named entity 'PARTIAL' named entity 'VACCINATED' named entity '5000' named entity 'RHESUS MONKEYS' named entity 'CORONAVIRUS VACCINE' named entity 'SAFETY' named entity 'SARS-ASSOCIATED CORONAVIRUS' named entity 'EFFICACY' named entity 'INACTIVATED' named entity 'ATYPICAL' named entity 'CHALLENGE' named entity 'DAY 7' named entity 'CLINICAL' named entity 'INDICES' named entity 'INFECTION' named entity '50%' named entity 'CLINICAL TRIALS' named entity 'SAFE' named entity 'FOLLOWING' named entity 'MUCOSAL' named entity 'CONTROL' named entity 'INDUCE' named entity 'ELICITED' named entity 'VACCINE' named entity 'MUCOSAL IMMUNITY' named entity 'CANDIDATE' named entity 'IMMUNE RESPONSES' named entity 'VIRAL' named entity 'VIRAL INFECTION' named entity 'SPECIFIC' named entity 'STRAIN' named entity 'COMPARED' named entity 'IMMUNIZATION' named entity 'DOSAGE' named entity 'MAYBE' named entity 'VIROLOGICAL' named entity '0.5' named entity 'NS-1' named entity 'CHEMICAL' named entity 'IMMUNITY' named entity 'INACTIVATED VACCINE' named entity 'MONKEYS' named entity 'VIREMIA' named entity 'ELICITED BY' named entity 'RESULTS' named entity 'RHESUS MONKEYS' named entity 'MONITORED' named entity 'SAR' named entity 'CORONAVIRUS' named entity 'EVALUATED' named entity 'SIDE EFFECTS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software